Ranbaxy Laboratories (RL) has received its first tentative approval from the US Food and drug administration ( FDA ) to manufacture and market
Ranbaxy Laboratories (RL) has received its first tentative approval from the US Food and drug administration ( FDA ) to manufacture and market lamivudine tablets that can be used in combination with other anti - retroviral agents (ARVs) to treat patients with HIV infection.
The approval has come after a number of quality checks and inspections by some of the most stringent agencies in the world including the US FDA.All the other ARVs including the present lamivudine tablets are at present being manufactured by Ranbaxy itself in its state of the art laboratories.The CEO of Ranbaxy Laboratories has said that the approval by the US FDA is a great achievement and a major step forward in making life saving ARV medicines available to more and more individuals suffering with AIDS in the developing countries and he also promised to make all efforts to obtain speedy approval for all the other ARVs being manufactured by Ranbaxy Laboratories.
